PT-141 (Bremelanotide): Evidence, Mechanism & Legal Status

PT-141 (bremelanotide, brand name Vyleesi) is a synthetic cyclic heptapeptide melanocortin-receptor agonist that acts on the brain to modulate sexual desire — a mechanism fundamentally different from the vascular action of PDE5 inhibitors such as sildenafil and tadalafil.8 It is unusual among popular peptides in having a real FDA approval and Phase 3 randomized-trial evidence behind it. This monograph separates the proven from the hyped.

This article is informational and editorial content for research and educational purposes only. It is not medical advice, not a protocol to follow, and not a sourcing or buying guide. PT-141 acutely raises blood pressure, can cause persistent skin and gum darkening, and is FDA-approved for one narrow population only. Dosing figures are reported strictly as seen in the FDA label and published trials. Consult a licensed clinician before any health decision.

What is PT-141 and how does it work?

Bremelanotide is a synthetic cyclic heptapeptide — a deaminated derivative and likely active metabolite of melanotan II (MT-II), itself derived from α-melanocyte-stimulating hormone (α-MSH).7 Its cyclic architecture confers resistance to peptidase degradation and is thought to support receptor engagement that outlasts its plasma half-life.12 It is a non-selective agonist across the melanocortin receptor family (MC1R, MC3R, MC4R, MC5R), sparing only MC2R (the ACTH receptor); affinity is highest at MC1R, followed by MC4R.8

The pro-sexual effect is CNS-mediated. Bremelanotide activates MC4R in hypothalamic circuitry — the paraventricular nucleus and medial preoptic area — modulating the dopaminergic arousal pathway that governs desire.8 This is mechanistically distinct from PDE5 inhibitors, which act peripherally on corpus-cavernosum vascular smooth muscle; bremelanotide does not act on the vasculature to produce an erection but on the brain's desire and arousal centers.11 From a functional-medicine framing, this targets a central neuroendocrine node of desire rather than a downstream vascular symptom — but it is an acute agonist, not a root-cause correction of hormonal, relational, or metabolic drivers of low libido.

Pharmacokinetically, subcutaneous 1.75 mg gives near-100% bioavailability, a Tmax of about 0.5 to 1 hour, roughly 21% plasma protein binding, and an elimination half-life of about 2.7 hours (range ~1.9 to 4.0 h) — notably not the ~11 h sometimes misstated.914 Metabolism is by peptidase hydrolysis with minimal CYP involvement, so CYP-mediated drug-interaction risk is low.7 Despite the short half-life, perceived effects are reported to persist several hours, consistent with sustained central receptor engagement.9

What is the evidence by indication?

The single best-evidenced use is premenopausal HSDD, the only FDA-approved indication and the only one with Phase 3 RCT support. The two pivotal RECONNECT trials are registered as NCT02333071 and NCT02338960 — identical 24-week, randomized, double-blind, placebo-controlled multicenter studies enrolling roughly 1,267 premenopausal women with acquired, generalized HSDD.34 Women self-administered 1.75 mg subcutaneous bremelanotide or placebo on-demand via autoinjector.1

In RECONNECT both co-primary endpoints were met. Desire (FSFI-Desire domain change versus placebo) improved by an integrated +0.35 (effect size ≈0.39), and distress (FSDS-DAO Item 13) fell by an integrated −0.33 (effect size ≈0.27), both P<0.001 integrated.1 The honest magnitude matters: these effects are statistically significant but small, and authors themselves benchmarked them as comparable to flibanserin and to SSRIs for anxiety.1 Critically, the key secondary endpoint — the number of satisfying sexual events — did not significantly differ from placebo (integrated P=0.630); only a post-hoc analysis of the proportion of encounters rated satisfying favored the drug.1 Placebo responder rates were about 35 to 36%, and authors estimated roughly 40% of the relative improvement was attributable to placebo; withdrawal was markedly higher on drug than placebo.1 A 52-week open-label extension showed sustained desire improvement.2

For erectile dysfunction, bremelanotide is the most-studied melanocortinergic compound but development stopped at Phase 2.11 Early intranasal Phase 1/2A studies showed dose-dependent increases in erectile activity with a roughly 30-minute onset; the foundational double-blind study appeared in Int J Impot Res in 2004.10 A larger Phase 2 program (~726 men, intranasal 7.5 to 15 mg) reported significant IIEF improvements and a positive clinical response in roughly one-third of treated men, including some PDE5-failures studied as a sildenafil 'salvage' combination.13 But the FDA paused intranasal trials in 2007 over blood-pressure increases and that development stopped in 2008; ED remains an off-label, unapproved use, and Vyleesi is explicitly not indicated in men.146 General libido enhancement in healthy people and use in postmenopausal women have no qualifying controlled efficacy evidence and are graded D.1

What doses appear in the literature?

Reported strictly as information, not a protocol. The FDA-approved Vyleesi regimen is 1.75 mg subcutaneously by autoinjector into the abdomen or thigh, on-demand, at least 45 minutes before anticipated sexual activity, with a ceiling of one dose per 24 hours and no more than eight doses per month; the label advises discontinuing after eight weeks if symptoms do not improve.514 The approved product is a prefilled single-dose autoinjector requiring no reconstitution. Historical ED research used a different route and dose — intranasal 7.5 to 20 mg on-demand — a route and dose range never approved and discontinued for safety.1014 Grey-market lyophilized 'research-chemical PT-141' vials requiring reconstitution are not the FDA-approved product.

How safe is PT-141?

The most common adverse reactions in RECONNECT were nausea at about 40% versus roughly 1.3% on placebo (median onset ~30 min, ~98% mild–moderate, ~8.1% discontinuing because of it), flushing ~20%, injection-site reactions ~13%, and headache ~11 to 12%.18 Bremelanotide produces transient placebo-adjusted blood-pressure increases of roughly +3 mmHg systolic and +2 mmHg diastolic, peaking 0 to 2 hours post-dose and resolving within about 8 to 10 hours — the signal that halted intranasal ED development and that underpins the cardiovascular contraindications.14

A distinctive risk is MC1R-mediated focal hyperpigmentation of the face, gums, and breasts; risk is higher with more frequent dosing (more than eight doses per month) and in darker skin, and the discoloration may not resolve after stopping — the concern most relevant to high-frequency off-label grey-market dosing.514 LiverTox assigns a hepatotoxicity likelihood of D ('possible rare cause'), with one documented case of acute hepatitis resolving on discontinuation.7 Bremelanotide slows gastric emptying, reducing oral bioavailability of co-administered drugs — notably oral naltrexone, risking treatment failure.5 It is contraindicated in uncontrolled hypertension and known cardiovascular disease and is not recommended in pregnancy.5

What is the FDA and WADA status in 2026?

Bremelanotide is FDA-approved as Vyleesi (NDA 210557, approved June 21, 2019; originator Palatin Technologies) for premenopausal women with acquired, generalized HSDD — and for nothing else.6 'PT-141' sold as a compounded or research-chemical product is distinct from approved Vyleesi: its eligibility under Section 503A is part of the ongoing FDA peptide-compounding review, with a Pharmacy Compounding Advisory Committee discussion expected in July 2026, and re-categorization is not the same as approval.1718 Vials labeled 'research use only, not for human consumption' do not authorize human self-administration and carry no identity or purity guarantee.19

For athletes, bremelanotide is not named on the 2026 WADA Prohibited List, in force since January 1, 2026.15 Because an FDA-approved formulation exists, the S0 catch-all for non-approved substances does not blanket-prohibit legitimate Vyleesi — but grey-market PT-141 labeled 'not for human use' could fall under S0, so athletes should verify any product via GlobalDRO and their federation.16

Bottom line. PT-141 is one of the few peptides with genuine Grade-A human RCT evidence and an FDA approval — yet the approval is narrow (premenopausal HSDD) and the effect is honest-to-modest, with no demonstrated edge over placebo on satisfying sexual events. The principal real-world cautions are the transient pressor effect, frequent nausea, and potentially permanent hyperpigmentation with high-frequency off-label use. From a root-cause perspective, it is an acute central agonist that can mask but does not resolve the hormonal, relational, or metabolic drivers of low desire. Regulatory facts here are current as of June 2026 and should be re-verified after the July 2026 PCAC review.